SCHEMBL18650712

SCHEMBL18650712

CC[C@H]1O[C@@H](OC[C@H]2O[C@@H](OC[C@H]3OC(O)[C@H](OC(=O)c4ccccc4)[C@@H](OC(=O)c4ccccc4)[C@@H]3OC(=O)c3ccccc3)[C@H](OC(=O)c3ccccc3)[C@@H](OC(=O)c3ccccc3)[C@@H]2OC(=O)c2ccccc2)[C@H](OC(=O)c2ccccc2)[C@@H](C)[C@@H]1C

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 11/20 0.39
LGALS3 P17931 2/20 0.38
LGALS9 O00182 1/20 0.38
LGALS1 P09382 1/20 0.38
LGALS7; LGALS7B P47929 1/20 0.38
PTPN2 P17706 2/20 0.37
PTPN6 P29350 2/20 0.37
PTPN11 Q06124 2/20 0.37
F11 P03951 2/20 0.37
SELP P16109 2/20 0.36
MEN1 O00255 1/20 0.36
USP2 O75604 1/20 0.36
POLB P06746 1/20 0.36
KMT2A Q03164 1/20 0.36
ELANE P08246 1/20 0.36
NT5E P21589 1/20 0.36
SELE P16581 1/20 0.35
LGALS4 P56470 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20226171 0.99 LGALS9 (0.39) PTPN1LGALS3LGALS9LGALS1LGALS7; LGALS7B
SCHEMBL18650669 0.99 LGALS9 (0.39) PTPN1LGALS3LGALS9LGALS1LGALS7; LGALS7B
SCHEMBL18650701 0.91 PTPN1 (0.46) PTPN1PTPN2PTPN11F11MEN1
SCHEMBL18650717 0.91 LGALS3 (0.40) PTPN1LGALS3LGALS9LGALS1LGALS7; LGALS7B
SCHEMBL18650683 0.90 PTPN1 (0.44) PTPN1LGALS3LGALS9LGALS1LGALS7; LGALS7B
SCHEMBL20226177 0.90 PTPN1 (0.44) PTPN1LGALS3LGALS9LGALS1LGALS7; LGALS7B
SCHEMBL18650711 0.87 PTPN1 (0.38) PTPN1LGALS3LGALS9LGALS1LGALS7; LGALS7B
SCHEMBL20257764 0.86 LGALS9 (0.41) PTPN1LGALS3LGALS9LGALS1LGALS7; LGALS7B
SCHEMBL9880223 0.85 LGALS3 (0.38) PTPN1LGALS3LGALS9LGALS1LGALS7; LGALS7B
SCHEMBL9880217 0.85 LGALS3 (0.38) PTPN1LGALS3LGALS9LGALS1LGALS7; LGALS7B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180154014-A1 BETA-1,6-GLUCAN CETUXIMAB ANTIBODY CONJUGATES IMMUNEXCITE, INC. 2018-06-07 US disclosed
US-20170081428-A1 IMMUNOMODULATING BETA-1,6-D-GLUCANS INNATE BIOTHERAPEUTICS, LLC 2017-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180154014-A1 BETA-1,6-GLUCAN CETUXIMAB ANTIBODY CONJUGATES CD47, ERBB3, FUT6 PTPN1 708/4885LGALS3 28/4885LGALS9 71/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.